Johnson & Johnson (NYSE:JNJ) Big Money Sentiment Index Improved in Q4 2017 to 0.87

May 16, 2018 - By Jenna Rose

Johnson & Johnson (NYSE:JNJ) Corporate Logo

Johnson & Johnson’s Sentiment

In Q4 2017 Johnson & Johnson (NYSE:JNJ) big money sentiment increased to 0.87, according to SEC.gov filings. So its up 0.04, from 2017Q3’s 0.83. 797 hedge funds opened new and increased stock positions, while 919 decreased and sold stock positions in Johnson & Johnson so the sentiment improved. Funds own 1.72 billion shares, up from 1.71 billion shares in 2017Q3. Funds holding Johnson & Johnson in top 10 decreased from 580 to 572 for a decrease of 8. In total 35 funds closed positions, 884 reduced and 654 increased. Also 143 funds bought new Johnson & Johnson stakes.

Largest Johnson & Johnson Investors

As of Q4 2017 Robert Wood Johnson Foundation has 100% invested in Johnson & Johnson. As of Q4 2017, 25,000 shares of Johnson & Johnson are owned by Cincinnati Indemnity Co. Pettee Investors Inc. reported 145,012 shares. The Pennsylvania-based fund Armstrong Henry H Associates Inc have invested about 11.8% of the active investment manager’s stock portfolio in Johnson & Johnson. The Georgia-based fund Boulegeris Investments Inc. looks positive on Johnson & Johnson, owning 125,211 shares.

Johnson & Johnson, together with its subsidiaries, researches and develops, makes, and sells various products in the health care field worldwide.The firm is valued at $337.36 billion. It operates through three divisions: Consumer, Pharmaceutical, and Medical Devices.265.36 is the P/E ratio. The Consumer segment offers baby care products under the JOHNSONÂ’S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSONÂ’S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

JNJ reached $125.78 during the last trading session after $0.65 change.Johnson & Johnson has volume of 1.54M shares. Since May 16, 2017 JNJ has risen 1.12% and is uptrending. JNJ underperformed the S&P500 by 10.43%.

Investors wait Johnson & Johnson (NYSE:JNJ)’s quarterly earnings on July, 17., Zacks reports. Analysts forecast $2.05 earnings per share, which is $0.22 up or 12.02 % from 2017’s $1.83 earnings per share. If $2.05 is reported, JNJ’s profit will reach $5.50B for 15.34 P/E. Wall Street now predicts -0.49 % negative EPS growth despite Johnson & Johnson previous quarter’s EPS of $2.06.

Centurylink Investment Mngmt holds 40,134 shs. Smithfield Trust invested in 69,405 shs or 1.18% of the stock. Glovista Invests Ltd owns 4,610 shs or 0.13% of their US capital. Gould Asset Management Limited Ca has invested 0.09% of its capital in Johnson & Johnson (NYSE:JNJ). Rock Point Advisors Lc, a Vermont-based fund reported 7,410 shs. Linscomb And Williams Incorporated owns 65,134 shs for 0.75% of their capital. Arrowgrass Capital Prns (Us) Limited Partnership owns 0.05% invested in Johnson & Johnson (NYSE:JNJ) for 36,997 shs. 133,390 were accumulated by Braun Stacey Incorporated. Kemper Master Retirement Tru has invested 1.07% of its capital in Johnson & Johnson (NYSE:JNJ). Dixon Hubard Feinour And Brown Va invested in 3.21% or 84,797 shs. Moreover, Anchor Cap Advisors Ltd Company has 0.97% invested in Johnson & Johnson (NYSE:JNJ) for 197,400 shs. Counselors Of Maryland Ltd invested in 10,055 shs or 0.07% of the stock. Westwood Mgmt Corp Il stated it has 0.09% of its capital in Johnson & Johnson (NYSE:JNJ). Thomas J Herzfeld Advisors invested in 59 shs or 0% of the stock. Nebraska-based Bridges Mgmt has invested 1.27% in Johnson & Johnson (NYSE:JNJ).

Johnson & Johnson had 1 sale and 0 insider buys since February 15, 2018. This’s net activity of $20.17 million.

Johnson & Johnson (NYSE:JNJ) Ratings Coverage

A total of 10 analysts rate Johnson & Johnson (NYSE:JNJ) as follows: 5 “Buy”, 4 “Hold” and 1 “Sell”. Тherefore 50% are bullish. (NYSE:JNJ) has 17 ratings reports on 16 May 2018 according to StockzIntelligence. The company rating was maintained by Deutsche Bank on Wednesday, April 18. On Friday, April 20 Credit Suisse maintained Johnson & Johnson (NYSE:JNJ) rating. Credit Suisse has “Outperform” rating and $151 target. In Thursday, April 12 report Credit Suisse upgraded it to “Buy” rating and $15400 target. On Wednesday, January 24 Stifel Nicolaus maintained Johnson & Johnson (NYSE:JNJ) with “Hold” rating. On Wednesday, April 18 the stock of Johnson & Johnson (NYSE:JNJ) has “Buy” rating given by Wells Fargo. On Tuesday, February 27 the firm earned “Neutral” rating by Citigroup. On Tuesday, January 2 JP Morgan downgraded the shares of JNJ in report to “Neutral” rating. On Tuesday, January 23 the company was maintained by BTIG Research. On Friday, March 23 Jefferies maintained Johnson & Johnson (NYSE:JNJ) rating. Jefferies has “Buy” rating and $16100 target. On Wednesday, April 18 Stifel Nicolaus maintained the shares of JNJ in report with “Hold” rating.

For more Johnson & Johnson (NYSE:JNJ) news published recently go to: Livetradingnews.com, Seekingalpha.com, Seekingalpha.com, 247Wallst.com or Seekingalpha.com. The titles are as follows: “Johnson & Johnson (NYSE:JNJ) Stock Oversold” published on May 03, 2018, “Johnson & Johnson: Waiting On The Wave” on May 11, 2018, “What Can I Expect To Make If I Invest In Johnson & Johnson Today?” with a publish date: May 16, 2018, “Johnson & Johnson Commits to Yet Another Dividend Hike” and the last “More states sue over opioid epidemic” with publication date: May 16, 2018.

Johnson & Johnson (NYSE:JNJ) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.